Media Summary: GENERAL SESSION 1 – GS1-01 KEYNOTE-522: GENERAL SESSION 1 GS1-02 Final results of KEYNOTE-355: Randomized, double-blind, GS3-02. Updated overall survival (OS) results from the
Sabcs 2021 Phase 3 Study - Detailed Analysis & Overview
GENERAL SESSION 1 – GS1-01 KEYNOTE-522: GENERAL SESSION 1 GS1-02 Final results of KEYNOTE-355: Randomized, double-blind, GS3-02. Updated overall survival (OS) results from the Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival ... Breast Cancer experts Dr. Virginia Kaklamani and Dr. Komal Jhaveri discuss the recent announcement of Dr. Virginia Kaklamani, co-director of the San Antonio Breast Cancer Symposium, and Dr. Sara Tolaney, chief of the Division of ...
This session took place at 5:30 p.m. Thursday, Dec. 12, 2024. It was a Poster Spotlight session. YOUTUBE CHAPTERS 0:00 ... Charles Coombes, MD, PhD, Imperial College London, London, UK, highlights key learnings from this years San Antonio Breast ... Trastuzumab deruxtecan vs physician's choice in patients with HER2+ unresectable and/or metastatic breast cancer previously ... Saba Shaikh, MD, a breast cancer oncologist at the Mays Cancer Center at UT Health San Antonio, and Shanu Modi, MD, ... GS3-05. Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ ... Dr. Bora Lim speaking at the San Antonio Breast Cancer Symposium on Thursday, December 8th 2022 #
One question we always hear is, "What will change on Monday morning?" So, we designed a CME program to answer precisely ... Spotlight Poster Discussion 5 - Life after breast cancer: Cardiac health, fertility preservation, and returning to life Ovarian reserve ... Michael Gnant, MD, Medical University of Vienna, Vienna, Austria, discusses the San Antonio Breast Cancer Symposium ...
